Endo International falls as 'frozen shoulder' therapy fails mid-stage trial
01/07/2022 14:19
** Endo International's ENDP.O shares fall 12% to 41 cents
premarket
** Co's experimental therapy collagenase clostridium
histolyticum (CCH) for treatment of "frozen shoulder" fails to
meet key goal in mid-stage study of 198 patients urn:newsml:reuters.com:*:nPn1YT1XVa
** Participants receiving up to three doses of CCH showed
some improvement, but the difference was not statistically
significant compared to placebo - co
** James Tursi, Endo executive VP for global R&D says co
will be "reevaluating" its path forward for the treatment
** Stock down 88% YTD, up to last close
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Endo International
See all newsBrief: Endo International PLC Files For Offering Of Up To 31.1 Million Common Shares By The Selling Stockholders - SEC Filing
Brief: Par Pharmaceutical Issues Voluntary Nationwide Recall Of Seven Lots Of Treprostinil Injection
Brief: Endo International Says Wholly-Owned Subsidiary Endo Finance Priced Its $1.5 Bln Senior Secured Seven-Year Term Loan
Brief: Endo, Inc. Announces Pricing Of $1 Bln Of Senior Secured Notes
Brief: Endo Announces Proposed Private Offering Of Senior Secured Notes